Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Braveheart Investment Group is an AIM-listed strategic investment firm focused on high-growth potential technology businesses with a strong emphasis on life sciences and healthcare. It holds majority or significant stakes in several innovative biotech firms including Kirkstall Limited (organ-on-a-chip technology) and Paraytec Limited (rapid pathogen detection). Recent developments include Kirkstall's expansion into China with its Quasi Vivo® products aimed at reducing animal testing in drug safety assessments, and Paraytec's progress toward commercializing rapid diagnostic tools for bloodstream infections like sepsis.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Braveheart Investment Group.